[go: up one dir, main page]

WO2017011820A3 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Download PDF

Info

Publication number
WO2017011820A3
WO2017011820A3 PCT/US2016/042680 US2016042680W WO2017011820A3 WO 2017011820 A3 WO2017011820 A3 WO 2017011820A3 US 2016042680 W US2016042680 W US 2016042680W WO 2017011820 A3 WO2017011820 A3 WO 2017011820A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/042680
Other languages
French (fr)
Other versions
WO2017011820A2 (en
Inventor
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Ashok Bhandari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Priority to CR20180029A priority Critical patent/CR20180029A/en
Priority to BR112018000691A priority patent/BR112018000691A2/en
Priority to CA2991984A priority patent/CA2991984A1/en
Priority to EP16825301.1A priority patent/EP3341011A4/en
Priority to JP2018501178A priority patent/JP6858174B2/en
Priority to HK19101174.5A priority patent/HK1259149B/en
Priority to AU2016293619A priority patent/AU2016293619B2/en
Priority to HK19100122.0A priority patent/HK1257747A1/en
Priority to CN201680049562.2A priority patent/CN108348580B/en
Priority to US15/745,371 priority patent/US10787490B2/en
Priority to KR1020187004612A priority patent/KR102513978B1/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Priority to MX2018000542A priority patent/MX384213B/en
Priority to EA201890325A priority patent/EA035733B9/en
Priority to UAA201801482A priority patent/UA123772C2/en
Publication of WO2017011820A2 publication Critical patent/WO2017011820A2/en
Publication of WO2017011820A3 publication Critical patent/WO2017011820A3/en
Priority to PH12018500086A priority patent/PH12018500086A1/en
Priority to IL256827A priority patent/IL256827A/en
Priority to DO2018000010A priority patent/DOP2018000010A/en
Priority to NI201800008A priority patent/NI201800008A/en
Priority to SV2018005614A priority patent/SV2018005614A/en
Priority to ECIEPI20182929A priority patent/ECSP18002929A/en
Priority to CONC2018/0000349A priority patent/CO2018000349A2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
PCT/US2016/042680 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Ceased WO2017011820A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
UAA201801482A UA123772C2 (en) 2015-07-15 2016-07-15 INTERLEUKIN-23 RECEPTOR PETTIDE INHIBITOR AND METHOD OF TREATMENT OF INFLAMMATORY INTESTINAL DISEASE (IBD)
MX2018000542A MX384213B (en) 2015-07-15 2016-07-15 PEPTIDE INHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES.
CA2991984A CA2991984A1 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP16825301.1A EP3341011A4 (en) 2015-07-15 2016-07-15 INTERLEUKIN-23 RECEPTOR INHIBITOR PEPTIDES AND THEIR USE IN TREATING INFLAMMATORY DISEASES
JP2018501178A JP6858174B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of the interleukin 23 receptor, and their use for treating inflammatory diseases
HK19101174.5A HK1259149B (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2016293619A AU2016293619B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112018000691A BR112018000691A2 (en) 2015-07-15 2016-07-15 interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases
CN201680049562.2A CN108348580B (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US15/745,371 US10787490B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR1020187004612A KR102513978B1 (en) 2015-07-15 2016-07-15 Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
CR20180029A CR20180029A (en) 2015-07-15 2016-07-15 POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES
EA201890325A EA035733B9 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HK19100122.0A HK1257747A1 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PH12018500086A PH12018500086A1 (en) 2015-07-15 2018-01-09 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
DO2018000010A DOP2018000010A (en) 2015-07-15 2018-01-10 PEPTIDE INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES
IL256827A IL256827A (en) 2015-07-15 2018-01-10 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
NI201800008A NI201800008A (en) 2015-07-15 2018-01-11 INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
CONC2018/0000349A CO2018000349A2 (en) 2015-07-15 2018-01-15 Interleukin receptor peptide inhibitors 23
SV2018005614A SV2018005614A (en) 2015-07-15 2018-01-15 PEPTIDIC INHIBITORS OF INTERLEUCINE RECEIVER 23 AND USE TO TREAT INFLAMMATORY DISEASES
ECIEPI20182929A ECSP18002929A (en) 2015-07-15 2018-01-15 INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
USPCT/US15/40658 2015-07-15
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 2015-07-15
US201562264820P 2015-12-08 2015-12-08
US62/264,820 2015-12-08
US201662281123P 2016-01-20 2016-01-20
US62/281,123 2016-01-20

Publications (2)

Publication Number Publication Date
WO2017011820A2 WO2017011820A2 (en) 2017-01-19
WO2017011820A3 true WO2017011820A3 (en) 2017-02-23

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/042680 Ceased WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (23)

Country Link
EP (1) EP3341011A4 (en)
JP (1) JP6858174B2 (en)
KR (1) KR102513978B1 (en)
CN (1) CN108348580B (en)
AU (1) AU2016293619B2 (en)
BR (1) BR112018000691A2 (en)
CA (1) CA2991984A1 (en)
CL (3) CL2018000128A1 (en)
CO (1) CO2018000349A2 (en)
CR (1) CR20180029A (en)
DO (1) DOP2018000010A (en)
EA (1) EA035733B9 (en)
EC (1) ECSP18002929A (en)
HK (1) HK1257747A1 (en)
IL (1) IL256827A (en)
MX (1) MX384213B (en)
NI (1) NI201800008A (en)
PE (1) PE20180571A1 (en)
PH (1) PH12018500086A1 (en)
SG (1) SG10201912066SA (en)
SV (1) SV2018005614A (en)
UA (1) UA123772C2 (en)
WO (1) WO2017011820A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125503C2 (en) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Substituted tricyclic compounds as fgfr inhibitors
KR102236829B1 (en) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 Hepcidin analogues and uses therof
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20170028307A (en) 2014-05-16 2017-03-13 프로타고니스트 테라퓨틱스, 인코포레이티드 47 47 integrin thioether peptide antagonists
SG11201700327WA (en) 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
UA121669C2 (en) 2015-02-20 2020-07-10 Інсайт Корпорейшн BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN112566912A (en) 2018-05-04 2021-03-26 因赛特公司 Salts of FGFR inhibitors
SI3788047T1 (en) 2018-05-04 2024-11-29 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
JP7670605B2 (en) * 2018-07-12 2025-04-30 プロタゴニスト セラピューティクス， インコーポレイテッド Peptide inhibitors of the interleukin-23 receptor and their use for treating inflammatory diseases - Patents.com
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110015978B (en) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
CA3145449A1 (en) * 2019-07-01 2021-01-07 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022000397A (en) * 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202515892A (en) * 2020-01-15 2025-04-16 美商健生生物科技公司 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL299529A (en) * 2020-06-29 2023-02-01 Univ Washington Human IL23 receptor binding polypeptides
CN116438456A (en) 2020-09-11 2023-07-14 格里姆普斯生物股份有限公司 Ex vivo protease activity assays for disease detection/diagnosis, staging, monitoring and treatment
KR20230110570A (en) * 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. Compositions of Peptide Inhibitors of the Interleukin-23 Receptor
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Lipidated peptide inhibitors of interleukin-23 receptor
UY39858A (en) * 2021-07-14 2023-02-28 Janssen Biotech Inc BICYCLIC PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
WO2023288028A2 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor
WO2023099669A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) * 2022-03-17 2023-11-07 北京大学 Staple peptide, preparation method and pharmaceutical application thereof
IL317902A (en) 2022-06-30 2025-02-01 Sanofi Sa New peptides as selective il-23 receptor antagonists
EP4622991A2 (en) * 2022-11-21 2025-10-01 Janssen Pharmaceutica NV Synthesis of a cyclic peptide
EP4652181A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Polycyclic peptide inhibitors of interleukin-23 receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
AU2024214418A1 (en) 2023-01-31 2025-09-18 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor
WO2024227437A1 (en) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 Preparation of peptide inhibitor of interleukin-23 receptor and use thereof
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025051912A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025051920A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US9523073B2 (en) * 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
SG11201700327WA (en) * 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Also Published As

Publication number Publication date
EA201890325A1 (en) 2018-06-29
CL2018003322A1 (en) 2019-01-18
JP2018522008A (en) 2018-08-09
EA035733B1 (en) 2020-07-31
PE20180571A1 (en) 2018-04-04
CL2018000128A1 (en) 2018-06-15
DOP2018000010A (en) 2018-03-30
CO2018000349A2 (en) 2018-07-10
AU2016293619B2 (en) 2021-02-25
EP3341011A4 (en) 2019-02-20
HK1259149A1 (en) 2019-11-29
CN108348580B (en) 2022-05-10
ECSP18002929A (en) 2018-03-31
KR20180030663A (en) 2018-03-23
CL2021000343A1 (en) 2021-08-06
SV2018005614A (en) 2018-05-22
SG10201912066SA (en) 2020-02-27
WO2017011820A2 (en) 2017-01-19
IL256827A (en) 2018-03-29
HK1257747A1 (en) 2019-10-25
CN108348580A (en) 2018-07-31
UA123772C2 (en) 2021-06-02
EA035733B9 (en) 2021-01-14
EP3341011A2 (en) 2018-07-04
JP6858174B2 (en) 2021-04-14
MX2018000542A (en) 2018-06-27
PH12018500086A1 (en) 2018-07-30
CR20180029A (en) 2018-06-05
KR102513978B1 (en) 2023-03-27
CA2991984A1 (en) 2017-01-19
BR112018000691A2 (en) 2018-09-18
AU2016293619A1 (en) 2018-02-01
MX384213B (en) 2025-03-14
NI201800008A (en) 2018-06-29

Similar Documents

Publication Publication Date Title
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MX2022000397A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
HK1246286A1 (en) Lrrk2 inhibitors and methods of making and using the same
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2017098328A3 (en) Therapeutic inhibitory compounds
HK1249104A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2015120062A3 (en) Therapeutic compounds and compositions
CN107406464A8 (en) Arginase inhibitor and its therapeutical uses
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
PH12017500114A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016014992A3 (en) Compositions for treatment, diagnosis and prognosis of diseases
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825301

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11201710859R

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2991984

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12018500086

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 256827

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2018-000008 I

Country of ref document: NI

Ref document number: 000053-2018

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2018501178

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/000542

Country of ref document: MX

Ref document number: CR2018-000029

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: NC2018/0000349

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016293619

Country of ref document: AU

Date of ref document: 20160715

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187004612

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201801482

Country of ref document: UA

Ref document number: 2016825301

Country of ref document: EP

Ref document number: 201890325

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825301

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018000691

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018000691

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180112

WWW Wipo information: withdrawn in national office

Ref document number: 2016825301

Country of ref document: EP